Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by cpacon Mar 28, 2019 9:43am

128 Views

Post# 29547340

News Release/Is Oncolytics working with Takeda Pharma?

Today's news release talks about the synergistic effects of using ONC's Pelareorep with a protease inhibitor in Multiple Myeloma... helping to confirm the theory that ONC's treatment helps overcome drug resistance in harder to treat cancers ...
Now, I knew that ONC was working with both Merck and Celgene in the area of Multiple Myeloma, but today's NR says the animal study was done in combination with Bortezomib... AKA Velcade which is a Takeda Pharmaceutical product... was anyone aware of ONC working with Takeda or was this study done independently as a means of getting Takeda's attention?

Cheers,
CPAC

Bullboard Posts

Silvercorp to expand into Ecuador with C$200M Adventus acquisition